Mega Fin (India) (532105)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 6/9 suggests the company is not in acute financial distress based on reported metrics.
• ROCE of 10.87% shows some positive return on capital employed, though it conflicts with negative ROE and needs verification.
• Debt/Equity is N/A, so leverage appears low or absent; if truly debt-free, balance-sheet downside is limited.
• Profit growth of 100% indicates some reported improvement, but from a negligible or volatile base.

Concerns

• Latest quarter has ₹0 Cr sales and ₹0 Cr net profit; there is no real operating earning power to value.
• ROE is -10.90%, destroying book value; at P/B of 4.24, the market price is far above a shrinking ₹2.42 book value.
• P/E of 104.56 with zero latest-quarter profit is an unreliable valuation multiple.
• Current price ₹10.25 is below the stated 52-week range of ₹25.77–39.90, warning of data inconsistency or severe illiquidity.
• Zero dividend yield and zero sales growth provide neither income nor growth support.

AI Analysis

Mega Fin (India) is exactly the kind of micro-cap that requires every rupee to be checked twice. At ₹10.25, I am being asked to pay 104 times earnings for a company whose book value is just ₹2.42 — more than four times book — while the latest quarter reports zero sales and zero net profit. With ROE of -10.90%, shareholder equity is being eroded, not compounded. There is no dividend, no sales growth, and no promoter holding disclosure, so I lack evidence of owner-friendly behavior. The reported 100% profit growth is meaningless on a base of once-again zero profit; it is a low-base illusion. ROCE of 10.87% is a confusing, positive-looking number against a negative ROE and no revenue, so I treat it as an accounting artifact rather than proof of earning power. The Piotroski F-Score of 6/9 is mildly encouraging, but it cannot turn a business with no operating profits into a good investment. Even more troubling, the current price of ₹10.25 lies below the stated 52-week range of ₹25.77–39.90. In a liquid market that discrepancy should not occur; it signals bad data, illiquidity, or a capital event I cannot evaluate. I do not buy what I cannot understand. This is a possible turnaround, but the burden is on management to produce real revenue and sustainable positive ROE. Until then, I will keep this on the too-hard pile.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer